EES-200 40 MG
ERYTHROMYCIN (ERYTHROMYCIN ETHYLSUCCINATE) : 40 MG · DIN 00000299 · AMDIPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is EES-200?
EES-200 40 MG contains ERYTHROMYCIN (ERYTHROMYCIN ETHYLSUCCINATE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 00000299, held by AMDIPHARM LIMITED, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 22-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EES-200 used for?
Erythromycin is indicated for the treatment of infections caused by susceptible strains of designated microorganisms in upper and lower respiratory tract infections, skin and soft tissue infections, primary syphilis, diphtheria, erythrasma, pertussis, Legionnaires' disease, chlamydial infections, and acne vulgaris. It is also used for prophylaxis against bacterial endocarditis and recurrent attacks of rheumatic fever.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00000299 |
|---|---|
| Brand name | EES-200 |
| Generic / active ingredient | ERYTHROMYCIN (ERYTHROMYCIN ETHYLSUCCINATE) : 40 MG |
| Manufacturer | AMDIPHARM LIMITED |
| Strength | 40 MG |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01FA01 ERYTHROMYCIN |
| AHFS class | 08:12.12.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 22-Jun-2017 |
| Original market date | 1962-12-31 00:00:00 |
How is it stored and handled?
Store between 15 and 25 °C. Store granules between 15 and 25 °C.
How is it supplied?
ERYBID: bottles of 100, 250 and 500 ovaloid white Dispertab tablets. PCE: bottles of 100, 250 and 500 ovaloid pink-speckled white Dispertab tablets. EES Granules come in a 7 or 10-day MEM PAC containing 105 mL or 150 mL bottles for 7 or 10-day treatment.
Is ERYTHROMYCIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by PHARMA STULLN INC. (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01FA01 ERYTHROMYCIN. 2 of 47 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ERYTHROCIN I.V. | 1 G | POWDER FOR SOLUTION | AMDIPHARM LIMITED | MARKETED | DIN 00682276 |
| ERYTHROCIN I.V. | 500 MG | POWDER FOR SOLUTION | AMDIPHARM LIMITED | MARKETED | DIN 00682268 |
| ALTI-ERYTHROMYCIN TAB 250MG USP | 250 MG | TABLET (ENTERIC-COATED) | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00640263 |
| EES 600 TABLETS 600MG | 600 MG | TABLET | AMDIPHARM LIMITED | CANCELLED POST MARKET | DIN 00583782 |
| EES-200 CHEWABLE TBS (ERYPED) | 200 MG | TABLET | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00000604 |
| EES-400 | 400 MG / 5 ML | POWDER FOR SUSPENSION | AMDIPHARM LIMITED | CANCELLED POST MARKET | DIN 00453617 |
| EMYCIN ECT 250MG | 250 MG | TABLET (ENTERIC-COATED) | THE UPJOHN COMPANY OF CANADA | CANCELLED POST MARKET | DIN 00030899 |
| ERYBID | 500 MG | TABLET | AMDIPHARM LIMITED | CANCELLED POST MARKET | DIN 00893862 |
| ERYC DELAYED-RELEASE CAPSULES | 250 MG | CAPSULE (ENTERIC-COATED) | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00607142 |
| ERYC DELAYED-RELEASE CAPSULES | 333 MG | CAPSULE (ENTERIC-COATED) | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00873454 |
Who else supplies ERYTHROMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ERYTHROMYCIN appears in 767 registered pack listings across 11 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.